ERZOFRI

Welcome to the Brand page for “ERZOFRI”, which is offered here for Medicines for human purposes for the treatment of schizophrenia in adults; medicines for human purposes for the treatment of schizoaffective disorder in adults as mono therapy and as an adjunct to mood stabilizers or antidepressants; chemical preparations for pharmaceutical purposes, for the treatment of schizophrenia in adults; chemical preparations for pharmaceutical purposes, for treatment of schizoaffective disorder in adults as mono therapy and as an adjunct to mood stabilizers or antidepressants; biochemical medicines for the treatment of schizophrenia in adults; biochemical medicines for the treatment of schizoaffective disorder in adults as mono therapy and as an adjunct to mood stabilizers or antidepressants; pharmaceutical preparations for treatment of schizophrenia in adults; pharmaceutical preparations for treatment of schizoaffective disorder in adults as mono therapy and as an adjunct to mood stabilizers or antidepressants; chemico-pharmaceutical preparations for treatment of schizophrenia in adults; chemico-pharmaceutical preparations for treatment of schizoaffective disorder in adults as mono therapy and as an adjunct to mood stabilizers or antidepressants; injectable pharmaceuticals for treatment of schizophrenia in adults; injectable pharmaceuticals for treatment of schizoaffective disorder in adults as mono therapy and as an adjunct to mood stabilizers or antidepressants; antidepressants; dressings, medical;.

Its status is currently believed to be active. Its class is unavailable. “ERZOFRI” is believed to be currently owned by “Shandong Luye Pharmaceutical Co., Ltd.”